Opis Europe European Clinical Cro

  • Home Cover
Despite COVID-19
OPIS is able to ensure business activity with its client and stakeholders.
Distant but united we continue to work together for clinical research.
Opis is an European clinical cro and it is the best solution for your trials

Clinical CRO - full service

OPIS was founded in 1998 as a small Italian CRO. Over the past 21 years we have worked with passion and dedication to conquer the trust of clients and the scientific community, learning from each project and challenge convinced that investing in knowledge earns the highest interest. Today, OPIS is the number one Italian CRO, with more than 240 employees at headquarters. At international level, OPIS manages both local and international full-service studies thanks to its offices located throughout Europe.

From its beginning, OPIS has managed complex and demanding projects in terms of study rationale and design, treatment features and patient characteristics. With time, this has led to the advancement of our main strengths: helping clients single out the best solution by putting forward positive and interesting proposals, flexibility, responsiveness, qualified personnel, cohesive and organized teams, and sustained monitoring of project status. OPIS has always been driven by a passion for research, a thirst for knowledge, and the desire to offer a personalized service that meets client needs without ever breaching the ethical and legal requirements that govern the conduct of clinical studies.



Services

Clinical Research Solutions

Expertise

Oncology Oncology
Hematology Hematology
Cardiovascular Diseases Cardiovascular Diseases
Neurology Neurology
Respiratory Diseases Respiratory Diseases
Rheumatology Rheumatology
Immunology and Transplantation Immunology and Transplantation
Metabolism and Nutritional Disorders Metabolism and Nutritional Disorders
Ophthalmology Ophthalmology

In 21 years of combining medical, regulatory, statistical and technological expertise, OPIS has assisted over 40 different clients with interventional and non-interventional clinical trials. Full service projects in a wide range of therapeutic areas include various rare disease indications as well as pediatric studies. Currently, over 40% of trials managed by OPIS are oncology or onco-hematology trials. Other major therapeutic areas include ophthalmology, neurology and cardiology. OPIS has established collaboration with numerous international Sponsors on multi-country trials. In addition to phase I-IV drug-related trials, OPIS also holds experience in managing clinical investigations for medical and diagnostic devices and in nutraceutical/food supplement studies.


Since its founding, OPIS has had the opportunity to collaborate with highly qualified doctors, who with great commitment, experience and passion have made fundamental contributions to clinical research. Today more than ever, clinical research needs doctors, nursing staff, researchers, pharmaceutical companies and CROs for their considerable contribution to the fight against the great battle called COVID-19.

The hope is that thanks to global mobilization, innovation, clinical research and synergy from all, the right combination of drugs can be found to stop the pandemic, treating the respiratory complications that characterize it.

In this emergency, OPIS wishes to thank all the people, organizations and companies that are investing their know-how to ensure essential services for the entire community.

Deep gratitude particularly goes to all the healthcare personnel who, with sacrifice and vocation, are facing the COVID-19 emergency at the forefront and to all the people that work tirelessly every day and every night in hospital departments and facilities. Thanks to all those who face the disease first-hand and embrace an ethical choice to assist, comfort and give hope to all patients and their families.

With sincere esteem

OPIS s.r.l.

News

Blog
Blog

SOLNATIDE has been approved for the treatment of COVID-19 patients suffering from pulmonary oedema and acute respiratory...

Read More
Blog